These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 7492260)

  • 1. Glutamate receptor dysfunction and schizophrenia.
    Olney JW; Farber NB
    Arch Gen Psychiatry; 1995 Dec; 52(12):998-1007. PubMed ID: 7492260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains.
    Tsai G; Passani LA; Slusher BS; Carter R; Baer L; Kleinman JE; Coyle JT
    Arch Gen Psychiatry; 1995 Oct; 52(10):829-36. PubMed ID: 7575102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and indirect modulation of the N-methyl D-aspartate receptor.
    Marino MJ; Conn PJ
    Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):1-16. PubMed ID: 12769631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo.
    Del'guidice T; Beaulieu JM
    Mol Pharmacol; 2008 May; 73(5):1339-42. PubMed ID: 18314495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia.
    Zavitsanou K; Ward PB; Huang XF
    Neuropsychopharmacology; 2002 Nov; 27(5):826-33. PubMed ID: 12431856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia.
    Schwartz TL; Sachdeva S; Stahl SM
    Curr Pharm Des; 2012; 18(12):1580-92. PubMed ID: 22280435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged.
    Veerman SR; Schulte PF; de Haan L
    Pharmacopsychiatry; 2014 Jul; 47(4-5):121-30. PubMed ID: 25002292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia.
    Gao XM; Sakai K; Roberts RC; Conley RR; Dean B; Tamminga CA
    Am J Psychiatry; 2000 Jul; 157(7):1141-9. PubMed ID: 10873924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered glutamatergic and GABAergic mechanisms in the cingulate cortex of the schizophrenic brain.
    Benes FM
    Arch Gen Psychiatry; 1995 Dec; 52(12):1015-8; discussion 1019-24. PubMed ID: 7492253
    [No Abstract]   [Full Text] [Related]  

  • 14. Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression.
    Bennett M
    Aust N Z J Psychiatry; 2009 Aug; 43(8):711-21. PubMed ID: 19629792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and D1 receptor binding in rats.
    Toua C; Brand L; Möller M; Emsley RA; Harvey BH
    Neuroscience; 2010 Jan; 165(2):492-9. PubMed ID: 19854242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia.
    du Bois TM; Huang XF
    Brain Res Rev; 2007 Feb; 53(2):260-70. PubMed ID: 17014910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.
    Citrome L
    J Clin Psychiatry; 2014; 75 Suppl 1():21-6. PubMed ID: 24581451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?
    Farber NB; Wozniak DF; Price MT; Labruyere J; Huss J; St Peter H; Olney JW
    Biol Psychiatry; 1995 Dec; 38(12):788-96. PubMed ID: 8750036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia.
    Gulchina Y; Xu SJ; Snyder MA; Elefant F; Gao WJ
    J Neurochem; 2017 Nov; 143(3):320-333. PubMed ID: 28628228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.